Pillstats
Rx only · Film, Extended Release · Transdermal

Estradiol

Brands: Minivelle · Estradiol

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US11 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)4083
US makers2 labelers
Packages11
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 10 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$2.79$5.59$8.38$11.17Dec 2025Apr 2026Jul 2026
$9.716
Latest avg · Jul 22, 2026
+5%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

8.2K16K25K33K2025 Q12025 Q22025 Q32025 Q42026 Q1
28K
Rx · 2026 Q1
309K
Units dispensed
+30%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Noven Therapeutics, LLCunknown10SUPPLYING
A-S Medication Solutionsunknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Apr 16, 2021
    RECALLRecall (Class II): Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by: Noven Pharmaceuticals,…

    Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin. — Recalling firm: Noven Pharmaceuticals Inc — Nationwide within the United States

  • Apr 16, 2021
    RECALLRecall (Class II): Estradiol Transdermal System Delivers 0.0375 mg/day, 8 Systems/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami…

    Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin. — Recalling firm: Noven Pharmaceuticals Inc — Nationwide within the United States

  • Sep 7, 2018
    RECALLRecall (Class II): Minivelle (estradiol transdermal system) Patches, Delivers 0.05 mg/day, a) 2 count and 8 count boxes, Rx only, Mfd. by:…

    Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches. — Recalling firm: Noven Pharmaceuticals, Inc. — Nationwide

  • Sep 7, 2018
    RECALLRecall (Class II): Minivelle (estradiol transdermal system) Patches, Delivers 0.025 mg/day, 8 count boxes, Rx only, Mfd. by: Noven Pharmac…

    Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches. — Recalling firm: Noven Pharmaceuticals, Inc. — Nationwide

  • Sep 7, 2018
    RECALLRecall (Class II): Minivelle (estradiol transdermal system) Patches Delivers 0.1 mg/day, a) 2 count and b) 8 count boxes, Rx only, , Mfd. …

    Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches. — Recalling firm: Noven Pharmaceuticals, Inc. — Nationwide

  • Sep 7, 2018
    RECALLRecall (Class II): Minivelle (estradiol transdermal system) Patches, Delivers 0.075 mg/day, 8 count boxes, Rx only, Mfd. by: Noven Pharmac…

    Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches. — Recalling firm: Noven Pharmaceuticals, Inc. — Nationwide

  • May 4, 2018
    RECALLRecall (Class II): Minivelle (estradiol transdermal system) 0.0375 mg/day, 1 System per pouch (NDC 68968-6637-1), packaged in 8 pouches pe…

    Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin. — Recalling firm: Noven Pharmaceuticals, Inc. — Nationwide in the USA.

  • May 4, 2018
    RECALLRecall (Class II): Minivelle (estradiol transdermal system) 0.1 mg/day, 1 System per pouch (NDC 68968-6610-1), packaged in 8 pouches per b…

    Defective Delivery System: no longer meets the specification for shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin. — Recalling firm: Noven Pharmaceuticals, Inc. — Nationwide in the USA.

  • Apr 27, 2017
    RECALLRecall (Class III): Minivelle (estradiol Transdermal System) 0.1 mg per day, pack of 8 systems per carton, Rx only, Dist. by: Noven Therape…

    Defective Delivery System: Out of specification for peel force from the release liner specification during stability testing at 18M 25C/60%RH. — Recalling firm: Noven Pharmaceuticals, Inc. — Nationwide within US

  • Feb 25, 2015
    RECALLRecall (Class II): Minivelle (estradiol transdermal system) 0.05 mg/day, 8-count box, Rx only, Manufactured by Noven Pharmaceuticals, Inc.…

    Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions. — Recalling firm: Noven Pharmaceuticals, Inc. — Nationwide